• About online consultations

  • 30 Consultation


  • 60 Consultation

  • 30 min Review & 30 min Consultation
    ※Online consultation will be in the latter 30 minutes.
    ※Please send the manuscript by 2-5 days prior to the date of the session(consult@enago.com)

Dean Allan Handley

Country: Massachusetts, USA


Qualification: Ph.D. in Molecular Genetics, (College Medicine & Dentistry, Brunswick, NJ)



Communication style

Experienced mentor, will speak slow in easy English, and has interacted with ESL researchers.


  1. Instructor profile
Dean is a highly published researcher with over 80 first author papers in diverse subjects such as medicine, science and business. He has over 20 years of experience as an editor for many science and medical journals. Additionally, he has published numerous monographs, book chapters, abstracts, clinical articles, and FDA submissions: INDs, NDAs. Dean can therefore help you not only in dealing with difficult research questions and preparing your paper but also in applying for grants and publishing in high impact factor journals.

More highlights:
  • He possesses extensive experience in formatting according to diverse academic conventions and requirements .
  • He has a formal understanding of APA, CMS, AMA, CSE and IEEE conventions as required by diverse journals
  • He possesses excellent skills in editing, increasing authoritative delivery, removing superfluous language and can determine and augment the author’s intended meaning and conclusions
  • He is also well versed with selective word choice, grammar and sentence structure
In addition, Dean can offer specialized research consultation in the following areas:
  • Molecular Genetics
  • Marketing and Finance
  • Oncology and Haematology
Academic Positions
  • 1981-88   Adjunct Teaching Assistant Professor, Dept. Physiology, College of Physicians & Surgeons, Columbia University, NY
  • 1978-81   NHLBI Postdoctoral Fellow/Research Associate, Dept. Physiology, College of Physicians & Surgeons, Columbia University, NY
Professional Experience
  • 2007- Present   Principal and Founder, Veridicus Consulting LLC, Shrewsbury, MA 01545
  • 2002-2008    Executive Director Medical Communications and Scientific Affairs, Medical Affairs, Sepracor Inc., Marlborough, MA 01752
  • 1994-2002    Senior Director, Scientific Affairs, Sepracor Inc., Marlborough, MA 01752
  • 1993-94   Senior Fellow & Group Leader, Cardiovascular Dept., Sandoz Research Institute, Sandoz Inc., East Hanover, NJ 07936 (Novartis Inc.)
  • 1990-92   Fellow, Platelet Dept., Sandoz Research Institute, Sandoz Inc., East Hanover, NJ 07936 (Novartis Inc.)
  • 1981-89   Associate Fellow, Platelet Dept, Sandoz Research Institute, Sandoz Inc., East Hanover, NJ 07936 (Novartis Inc.)
Education
  • 1997-98   MBA Finance & Marketing; Boston Univ. Graduate School of Business, Boston, MA
  • 1976-78   PhD Molecular Genetics, College Medicine & Dentistry, Brunswick, NJ
  • 1973-76   MSc Biochemistry, Waksman Institute, Rutgers University, NJ
  • 1967-71   BSc Lycoming College, Williamsport, PA
Publications

Oncolcogy - Hematology Publications:
  • Stern DM, Nawroth P, Kisiel W, Handley DA, Drillings M, Bartos J (1984). A coagulation pathway on bovine aortic segments leading to generation of factor Xa and thrombin. J. Clin. Invest. 74:1910-1921.
  • Stern DM, Nawroth P, Marcum J, Handley DA, Kisiel W, Rosenberg R, Stern K (1985). Interaction of antithrombin III bovine aortic segments. Role of heparin in binding and enhanced anticoagulant activity. J. Clin. Invest. 75:272-279.
  • Stern DM, Nawroth P, Handley DA, Kisiel W (1985). A new endothelial cell-dependent pathway of coagulation. Proc. Natl. Acad. Sci. USA 82:2523-2527.
  • Nawroth PP, McCarthy D, Kisiel W, Handley DA, Stern DM (1985). Cellular processing of bovine factors X and Xa by cultured bovine aortic endothelial cells. J. Exp. Med. 162:559-572.
  • Nemecek GM, Coughlin SR, Handley DA, Moskowitz MA (1986). Stimulation of aortic smooth muscle cell mitogenesis by serotonin. Proc. Natl. Acad. Sci. USA 83:674-678.
  • Nawroth P, Handley DA, Esmon CT, Stern DM (1986). Interleukin-1 induces endothelial cell procoagulant while suppressing cell surface anticoagulant activity. Proc. Natl. Acad. Sci. USA 83:3460-3464.
  • Nawroth P, Bank I, Handley DA, Cassimeris J, Chess L, Stern D (1986). Endothelium is a target tissue for tumor necrosis factor/cachectin. J. Exp. Med. 163:1363-1375.
  • Houlihan WJ, Lee ML, Nemecek GM, Handley DA, Winslow CM, Jaeggi C (1987). Antitumor activity of SRI 62-834, a cyclic ether analogue of ET-18-OCH3. Lipids 22:884-890.
  • Stern DM, Handley DA, Nawroth PP (1988). Endothelium and the regulation of coagulation. In: Endothelial Cell Biology in Health and Disease (N. Simionescu, M. Simionescu, eds.), Plenum Publishing Corporation, New York. pp. 275-306.
  • Nawroth P, Handley DA, Matsueda G, De Wall R, Gerlach H, Blohm D, Stern DM (1988). Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas. J. Exp. Med. 168:637-647.
  • Nemecek GM, St. Denny IH, Van Valen RG, Glinka KG, McCarthy LA, Handley DA, Stutz A (1989). Terbinafine inhibits the mitogenic response to platelet-derived growth factor in vitro and neointimal proliferation in vivo. J. Pharmacol. Exp. Ther. 248:1167-1174.
  • Houlihan WJ, Cheon SH, Handley DA, Larson DA (1991). Synthesis and pharmacology of a novel class of long-lasting PAF receptor antagonists. J. Lipid Mediators 3:91-99.
  • Stern DM, Esposito C, Gerlach H, Ryan J, Handley DA, Nawroth P (1991). Endothelium and regulation of coagulation. Diabetes Care 14:160-166.
  • Tijburg PNM, Ryan J, Stern DM, Wollitzky B, Rimon S, Handley DA, Nawroth P, Sixma JJ, de Groot PG (1991). Activation of the coagulation mechanism on tumor necrosis factor stimulated cultured endothelial cells and their extracellular matrix. J. Biol. Chem. 266:12067-12074.
  • Houlihan W, Cheon S, Handley DA, Larson D (1993). Structural modification of 5-aryl-2, 3 dihydroimidazo [2,1-a] isoquinoline platelet activating factor receptor antagonists. J. Med. Chem. 36: 3098-3102.
  • Houlihan WJ, Lee ML, Munder P, Handley DA, Jaeggi SC, Winslow C (1994). Antitumor activity of a piperidine phospholipid. Drug Research 44:1348-1388.
  • Houlihan WJ, Munder P, Handley DA, Cheon SH, Parillo VA (1995). Antitumor activity of 5-aryl-2, 3 dihydroimidazo [2,1-a] isoquinolines. J. Med. Chem. 38:234-240.
  • Houlihan WJ, Munder P, Handley DA, Nemecek GA (1995). Preclinical pharmacology and possible mechanism of action of the novel antitumor agent 5-(4’-piperidinomethyl phenyl) 2,3-dihydroimidazo [2,1-a] isoquinoline. Drug Research 45:1133-1137.
  • Leff AR, Herrnreiter A, Naclerio R, Baroody FM, Handley DA, Munoz NM. (1997). Effect of enantiomeric forms of albuterol on stimulated secretion of granular protein from human eosinophils. Pul Pharmacol Ther 10:97-104.
  • Lake P, DeLeo J, Cerasoli F, Logdberg L, Weetall M, Handley D. Pharmacodynamic evaluation of the neutralization of endotoxin by PMX622 in mice. Antimicrob Agent Chemother 48:2987-92, 2004.
Cardiovascular Publications
  • Handley DA, Arbeeny CM, Witte LD, Chien S (1981). Colloidal gold-low density lipoprotein conjugates as membrane receptor probes. Proc. Natl. Acad. Sci. 78:368-371.
  • Handley DA, Arbeeny CM, Eder HA, Chien S (1981). Hepatic binding and internalization of low density lipoprotein-gold conjugates in rats treated with 17-ethinyl estradiol. J. Cell Biol. 90:778-787.
  • Chien S, Lee ML, Laufer L, Handley DA, Weinbaum S, Colin CG, Usami S (1981). Effects of oscillatory mechanical disturbance on macromolecular uptake by the arterial wall. Arteriosclerosis 1:326-336.
  • Chien S, Laufer L, Handley DA (1982). Vesicle distribution in arterial endothelium determined with ruthenium red as extracellular marker. J. Ultrastruct. Res. 79:198-206.
  • Handley DA, Arbeeny CM, Chien S (1983). Sinusoidal endothelial uptake of low-density lipoprotein-gold conjugates in perfused livers of ethinyl estradiol treated rats. Eur. J. Cell Biol. 30:266-271.
  • Handley DA, Chien S, Arbeeny CM (1983). Ultrastructure of hepatic cholesterol crystals in the hyper-cholesterolemic-diabetic rat. Pathol. Res. Pract. 177:13-21.
  • Handley DA, Witte L, Arbeeny CM, Goodman DS, Chien S. (1983). Ultrastructural visualization of low-density lipoproteins during receptor binding and cellular endocytosis. J. Ultrastruct. Res. 83:43-47.
  • Handley DA, Witte LD (1984). Platelet-derived growth factor labeled to colloidal gold for use as a mitogenic receptor probe. Eur. J. Cell Biol. 34:281-286.
  • Chien S, Fan FC, Lee ML, Handley DA (1984). Effects of arterial pressure on endothelial transport of macromolecules. Biorheology 21:631-641.
  • Stern DM, Nawroth P, Kisiel W, Handley DA, Drillings M, Bartos J (1984). A coagulation pathway on bovine aortic segments leading to generation of factor Xa and thrombin. J. Clin. Invest. 74:1910-1921.
  • Stern DM, Nawroth P, Marcum J, Handley DA, Kisiel W, Rosenberg R, Stern K (1985). Interaction of antithrombin III bovine aortic segments. Role of heparin in binding and enhanced anticoagulant activity. J. Clin. Invest. 75:272-279.
  • Stern DM, Nawroth P, Handley DA, Kisiel W (1985). A new endothelial cell-dependent pathway of coagulation. Proc. Natl. Acad. Sci. USA 82:2523-2527.
  • Liu CY, Handley DA, Chien S (1985). Biochemical characterization of thrombin-gold conjugates and ultrastructural studies of conjugate binding by fibrin. Analyt. Biochem.147: 49-56.
  • Nawroth PP, McCarthy D, Kisiel W, Handley DA, Stern DM (1985). Cellular processing of bovine factors X and Xa by cultured bovine aortic endothelial cells. J. Exp. Med. 162:559-572.
  • Handley DA (1985). Current approaches towards inhibition of proliferation in atherosclerosis. Drug Develop. Res. 6:167-176.
  • Handley DA, Chien S (1986). Ultrastructural studies of endothelial and platelet receptor binding of thrombin-colloidal gold probes. Eur. J. Cell Biol. 39:391-398.
  • Kaperonis AA, Handley DA, Chien S (1986). Fiber, crystals and other forms of HbS polymers in deoxygenated sickle erythrocytes. Am. J. Hematol. 21:269-275.
  • Handley DA, Van Valen RG, Melden MK, Saunders RN (1986). Suppression of rat carotid lesion development by the calcium channel blocker, PN 200-110. Am. J. Pathol. 124:88-93.
  • Nemecek GM, Coughlin SR, Handley DA, Moskowitz MA (1986). Stimulation of aortic smooth muscle cell mitogenesis by serotonin. Proc. Natl. Acad. Sci. USA 83:674-678
  • Nawroth P, Handley DA, Esmon CT, Stern DM (1986). Interleukin-1 induces endothelial cell procoagulant while suppressing cell surface anticoagulant activity. Proc. Natl. Acad. Sci. USA 83:3460-3464.
  • Nawroth P, Bank I, Handley DA, Cassimeris J, Chess L, Stern D (1986). Endothelium is a target tissue for tumor necrosis factor/cachectin. J. Exp. Med. 163:1363-1375.
  • Arbeeny CM, Rifici VA, Handley DA, Eder HA (1987). Binding and internalization of very low density lipoprotein remnants the perfused liver. Metabolism 36:1106-1113.
  • Goldberg IJ, Handley DA, Vanni T, Paterniti JR and Cornicelli J. A (1988). Membrane bound lipoprotein lipase on human monocyte-derived macro-phages: Localization by immuno-colloidal gold technique. Biochim. Biophys. Acta 959:220-228.
  • Nawroth P, Handley DA, Matsueda G, De Wall R, Gerlach H, Blohm D, Stern DM (1988). Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas. J. Exp. Med. 168:637-647.
  • Handley DA, Chien S. (1987). Applications of colloidal gold labeling related to vascular and endothelial function, hemostasis and receptor-mediated expression of plasma macromolecules. Eur. J. Cell Biol. 43:163-174.
  • Stern DM, Handley DA, Nawroth PP (1988). Endothelium and the regulation of coagulation. In: Endothelial Cell Biology in Health and Disease (N. Simionescu, M. Simionescu, eds.), Plenum Publishing Corporation, New York. pp. 275-306.
  • Stern DM, Esposito C, Gerlach H, Ryan J, Handley DA, Nawroth P (1991). Endothelium and regulation of coagulation. Diabetes Care 14:160-166.
  • Tijburg PNM, Ryan J, Stern DM, Wollitzky B, Rimon S, Handley DA, Nawroth P, Sixma JJ, de Groot PG (1991). Activation of the coagulation mechanism on tumor necrosis factor stimulated cultured endothelial cells and their extracellular matrix. J. Biol. Chem. 266:12067-12074.
  • Nemecek GM, St. Denny IH, Van Valen RG, Glinka KG, McCarthy LA, Handley DA, Stutz A (1989). Terbinafine inhibits the mitogenic response to platelet- derived growth factor in vitro and neointimal proliferation in vivo. J. Pharmacol. Exp. Ther. 248:1167-1174.
  • Handley DA (1995). Developmental preclinical therapies and clinical strategies in the treatment of vascular restenosis. Drugs Future 20:265-290.
  • Handley DA (1995). Experimental therapeutics and clinical studies in (re) stenosis. Micron 26:51-68.
  • Handley DA (1995). Developmental preclinical therapies and clinical strategies in the treatment of vascular restenosis. Drugs Future 20:265-290.
  • Handley DA, Hughes TE (1997). Pharmacological approaches and strategies for therapeutic modulation of fibrinogen. Thromb Res 87:1-36.
Inlammation - Pulmonary - Allergy Publications
  • Handley DA, Van Valen R, Melden M, Saunders RN (1984). Evaluation of dose and route effects of platelet activating factor-induced extravasation in the guinea pig. Thromb. Haemost. 52:34-36.
  • Handley DA, Arbeeny C, Lee M, Van Valen RG, Saunders RN (1984). Effect of platelet-activating factor on endothelial permeability of plasma albumin and lipoproteins. Immunopharmacology 8:137-142.
  • Handley DA, Lee ML, Saunders RN (1985). Evidence for a direct effect on vascular permeability of platelet-activating factor-induced hemo-concentration in the guinea pig. Thromb. Haemost. 54:756-759.
  • Handley DA, Van Valen RG, Melden MK, Flury S, Saunders RN (1986). Inhibition and reversal of endotoxin- aggregated IgG- and PAF-induced hypotension in the rat by SRI 63-072, a PAF receptor antagonist. Immuno-pharmacology 12:11-17.
  • Handley DA, Farley C, Saunders RN (1986). Evidence for distinct systemic extravasation effects of platelet activating factor, leukotrienes B4, C4, D4 and histamine in guinea pigs. Prostaglandins, Leukotrienes Med. 21:269-277.
  • Handley DA, Van Valen RG, Saunders RN (1986). Vascular responses of platelet-activating factor in the Cebus apella primate and inhibitory profiles of PAF antagonists SRI 63-072 and SRI 63-119. Immunopharmacology 11:175-182.
  • Handley DA, Tomesch J, Saunders R (1986). Inhibition of PAF-induced systemic responses in the rat, guinea pig, dog and primate by the receptor antagonist SRI 63-441. Thromb. Haemost. 56:40-45.
  • Handley DA, Van Valen RG, Tomesch JC, Melden MK, Jaffe JA, Ballard F, Saunders RN (1987). Biological properties of the receptor antagonist SRI 63-441 in the PAF and endotoxin models of hypotension in the rat and dog. Immunopharmacology 13:125-132.
  • Handley DA, Van Valen R, Tomesch JC, Saunders RN (1987). Pharmacological profiles of the PAF antagonist, SRI 63-675. Thromb. Haemost. 57:187-190.
  • Patterson R, Harris KE, Handley DA, Saunders RN (1987). Evaluation of the effect of a platelet activating factor (PAF) receptor antagonist on platelet activating factor and ascaris antigen-induced airway responses in rhesus monkeys. J. Lab. Clin. Med. 110:606-611.
  • Handley DA, Anderson R, Saunders R (1987). Inhibition by SRI 63-072 and SRI 63-119 of PAF-acether and immune complexes in the guinea pig. Eur. J. Pharmacol. 141:409-416.
  • Handley DA (1987). New developments for clinical applications for PAF antagonists. J. Clin. Exp. Med. 143:415-417.
  • Handley DA, Van Valen R, Melden M, Houlihan W, Saunders RN (1988). Biological effects of the orally-active PAF receptor antagonist SDZ 64-412. J. Pharmacol. Exp. Ther. 247:617-623.
  • Patterson R, Smith LJ, Harris KE, Handley DA (1988). Studies of platelet activating factor in rhesus monkeys and man. J. Clin. Exp. Med. 148:44-49.
  • Patterson R, Harris KE, Bernstein PR, Krell RD, Handley DA, Saunders RN (1989). Effects of combined receptor antagonists of leukotriene D4 (LTD4) and platelet activating factor (PAF) on rhesus airway responses to LTD4, PAF and antigen. Int. Arch. Allergy Appl. Immunol. 88:462-470.
  • Handley DA (1990). Preclinical and clinical pharmacology of platelet activating factor receptor antagonists. Med. Res. Rev. 10:351-370.
  • Havill AM, Van Valen RG, Handley DA (1990). Prevention of non-specific airway hyperreactivity after allergen challenge in guinea pigs by the PAF antagonist SDZ 64-412. Br. J. Pharmacol. 99:396-400.
  • Handley DA (1995). Experimental therapeutics and clinical studies in (re) stenosis. Micron 26:51-68.
  • Jafarian A, Handley DA, Biggs DF (1996). Effects of RS-albuterol on the development of antigen-mediated airway hyperreactivity in guinea pigs. Clin Rev Allergy Immunol 14: 91-100.
  • Handley DA (1996). R-albuterol. Preclinical and clinical pharmacology. Clin Rev Allergy Immun 14: 1-2.
  • Handley DA, Rubin PD (1996). Beta agonists: one product, two drug. J Respir Care Pract. Oct 101-108.
  • Leff AR, Herrnreiter A, Naclerio R, Baroody FM, Handley DA, Munoz NM. (1997). Effect of enantiomeric forms of albuterol on stimulated secretion of granular protein from human eosinophils. Pul Pharmacol Ther 10:97-104.
  • Jerussi TP, Caubet JF, McCray JE, Handley DA. (1998). Clinical endo-scopic evaluation of the gastroduodenal tolerance to (R)- ketoprofen, (R)-flurbiprofen, racemic ketoprofen and paracetamol: A randomized, single-blind, placebo-controlled trial. J Clin Pharmacol, 38:S19-S24.
  • Handley DA, Cervoni PS, McCray JE, McCullough J. (1998). Preclinical enantioselective pharmacology of R- and S- Ketorolac. J Clin Pharmacol, 38:S25-25.
  • Templeton AGB, Chapman ID, Morley J, Handley DA. (1998). Effects of S-salbutamol on isolated human bronchus. Pulmon Pharmacol, 108:111-117.
  • Handley DA, Graff F. (1998). Allergy drug research: Third generation antihistamines. Adv. Managers Respir. Ther. 7:33-36.
  • Handley, DA, Cervoni, P, McCray, JE, McCullough, JR. (1998). Preclinical enantioselective pharmacology of (R)- and (S) ketorolac. J Clin Pharmacol 38:25S-35S.
  • Handley, DA, Morley, J, Vaickus, L. (1998). Levalbuterol. Exp. Opin. Invest. Drugs 7(12):2027-2041.
  • Handley, DA. (1999). The asthma-like pharmacology and toxicology of (S)-isomers of ß agonists. J Allergy Clin Immunol 104: S69-S76.
  • Handley, DA. (1999). Advancement of the third generation of antihistamines. Ped Asthma, Allergy Immunol 13: 163-168.
  • Handley, DA, Tinkelman, D, Noonan, M, Rollins, TE, Snider, ME, Caron, J. (2000). Dose-response evaluation of levalbuterol versus racemic albuterol in patients with asthma. J Asthma 37L 319-328.
  • Handley, DA, Senanayake, CH, Dutczak, W, Benovic, JL, Walle, T, Penn, RB, Wilkinson, HS, Tanoury, GJ, Andersson, RGG, Johansson, F, Morley, J. (2002). Biological actions of formoterol isomers. Pul Pharmacol Ther 15:135-145.
  • Lake P, DeLeo J, Cerasoli F, Logdberg L, Weetall M, Handley D. Pharmacodynamic evaluation of the neutralization of endotoxin by PMX622 in mice. Antimicrob Agent Chemother 48:2987-92, 2004

Read More >> Read Less >>

Book an Appointment

Consultation

$79 | 30 minutes

Consultation

$149 | 60 minutes

30 min Review & 30 min Consultation

$149 | 60 minutes